International Consensus on Clinical Trial Endpoints in Autosomal Dominant Osteopetrosis
Autosomal Dominant Osteopetrosis (ADO) is a disorder of mineral metabolism caused by gene defects that impair osteoclast-mediated bone resorption and result in diffuse skeletal sclerosis and increased bone mineral density. There is no approved medical therapy for ADO; however, therapies are being developed that hasten the need for clinical trial readiness. A key part of this process is the development of a core set of endpoints for inclusion in both natural history and interventional studies for ADO. To identify these endpoints, we used a modified Delphi approach to reach consensus among panelists on prioritization of 92 candidate endpoints developed from a detailed literature search and panelist nomination. The international panel was comprised of 11 physicians from four countries (Canada, Finland, France, and the United States) with expertise in ADO plus clinical trials in metabolic bone diseases. After three rounds of anonymous voting, with a structured discussion prior to the final vote, complete consensus (100% agreement) was reached for prioritization of 1) imaging using dual-energy x-ray absorptiometry and plain radiographs, 2) patient-reported outcome measures of pain and global impression of change, 3) blood-based biomarkers of bone metabolism, and 4) clinical outcomes such as fracture and osteomyelitis. We recommend that the prioritized endpoints described in more detail in this manuscript be uniformly incorporated into therapeutic clinical trials and natural history studies in ADO. Consistent evaluation of endpoints in both natural history studies and investigational therapies, with appropriate standardization of the underlying methodologies, will facilitate comparison among therapeutic approaches and support the use of historical control data, ultimately leading to acceleration of therapeutic development for patients with ADO.
Authors
- Thomas O. Carpenter (ORCID: https://orcid.org/0000-0003-1328-6768)
- Erik Allen Imel (ORCID: https://orcid.org/0000-0002-7284-3467)
- Michael J. Econs (ORCID: https://orcid.org/0000-0003-0940-1911)
- Lynda E. Polgreen (ORCID: https://orcid.org/0000-0002-2881-6138)
- Netsanet Gebregziabher (ORCID: https://orcid.org/0009-0006-3358-1712)
- Eric T. Rush (ORCID: https://orcid.org/0000-0002-8147-7315)
- Martine Esther Cohen-Solal (ORCID: https://orcid.org/0000-0002-8582-8258)
- Laura Lowe Tosi (ORCID: https://orcid.org/0000-0001-8827-9883)
- Michael A. Levine (ORCID: https://orcid.org/0000-0003-0036-7809)
- Steven Wai Ing (ORCID: https://orcid.org/0000-0002-4343-6723)
- Outi Mäkitie (ORCID: https://orcid.org/0000-0002-4547-001X)
- Leanne Marie Ward (ORCID: https://orcid.org/0000-0003-1557-9185)
- Ziyue Liu (ORCID: https://orcid.org/0009-0008-8312-6608)
Institutions
- Indiana University Health (US)
- Children's Mercy Hospital (US)
- Karolinska University Hospital (SE)
- Children's Hospital of Philadelphia (US)
- Children's National (US)
- University of Helsinki (FI)
- University of Ottawa (CA)
- Inserm (FR)
- University of California, Los Angeles (US)
- The Lundquist Institute (US)
- Université Paris Cité (FR)
- Children's Hospital of Eastern Ontario (CA)
- Helsinki University Hospital (FI)
- The Ohio State University Wexner Medical Center (US)
- University of California System (US)
- Karolinska Institutet (SE)
- Yale University (US)
- Helsinki Children's Hospital (FI)
- Bioscar (FR)
- Hôpital Lariboisière (FR)
- Folkhälsans Forskningscentrum (FI)
- Harbor–UCLA Medical Center (US)
- Indiana University Indianapolis (US)
- Indiana University School of Medicine (US)
- The Ohio State University (US)
- Indiana University – Purdue University Indianapolis (US)
- University of Missouri–Kansas City (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Journal of Bone and Mineral Research
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1093/jbmr/zjag162
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00